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2ABSTRACT
The Effects of Nicotine Administration on Behavior and Markers of Brain Plasticity in a 
Rodent Model of Psychosis
by
Marla Perna
Schizophrenia affects about 1% of the population. A hallmark of the disorder is 
increased dopamine D2 receptor sensitivity in the brain. Studies have shown that 
schizophrenics smoke cigarettes at approximately 4 times the rate of the general 
population. It has been suggested that nicotine use is a form of self-medication for 
symptoms in schizophrenia. Smoking behaviors typically begin in adolescence. We 
assessed effects of nicotine on behavior and brain plasticity in an adolescent rodent 
model of schizophrenia with the goal of identifying targets for smoking cessation. 
Methods: Rats were neonatally treated with quinpirole (a D2/D3 agonist) or saline and 
sensitized to 0.3, 0.5, or 0.7 mg/kg (free base) nicotine or saline, every other day for 9 
days, and  locomotor activity was recorded. After behavioral testing, animals 
demonstrating sensitization to 0.5mg/kg nicotine were surgically implanted with a guide 
cannula, aimed at the nucleus accumbens core. After recovery, animals underwent 
microdialysis and in vivo samples were collected every 20 minutes for 300 minutes. 
Postmortem brains from animals exposed to 0.5mg/kg nicotine or saline were dissected 
and the nucleus accumbens and dorsal striatum were analyzed for brain-derived 
neurotrophic factor (BDNF), phosphorylated cAMP response element binding protein 
3(pCREB), and glial-cell derived neurotrophic factor (GDNF), all proteins involved in 
neuronal plasticity. Results: Animals neonatally treated with quinpirole and administered 
nicotine showed robust increases in locomotor sensitization and a 400% increase in 
dopamine overflow from the accumbens core, which was greater than all other groups. 
Nicotine administration led to increased accumbal BDNF levels, which was enhanced 
by neonatal quinpirole pretreatment. GDNF levels were also increased in control 
animals given nicotine, which was attenuated to control levels by neonatal quinpirole. 
Finally, pCREB levels were robustly increased in animals neonatally treated with 
quinpirole, an effect that was partially attenuated by adolescent nicotine treatment. 
These data on pCREB suggest a possible biological marker of anhedonia. In 
conclusion, it is apparent that nicotine results in a robust increase in behavioral activity 
and changes in neural proteins of brain plasticity that may serve as possible 
pharmaceutical targets for smoking cessation in schizophrenia. 
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8CHAPTER 1
INTRODUCTION
Smoking is a major health concern for the general public as well as those with a 
comorbid mental disorder. Specifically, the prevalence of smoking in the schizophrenic 
population is 4 times the rate of smoking in the general population, yet the motivation for 
this increase in smoking behaviors is largely unfounded. It has been suggested that 
adolescent smoking may precede the onset and diagnosis of schizophrenia in this 
population [1] that leads to the importance of this stage in development of schizophrenia 
and comorbid nicotine use.   
The most highly abused drug by schizophrenics is nicotine, which is the 
psychoactive ingredient in tobacco [1]. This set of experiments focused on the effects of 
nicotine on behavioral sensitization in a rodent model of schizophrenia and the 
relationship between adolescent nicotine exposure and proteins involved in brain 
plasticity. We used a rodent model of schizophrenia based on increased dopamine (DA)
D2 receptor function, a manipulation that has been shown to persist throughout the 
animal’s lifetime [2]. The time period preceding diagnosis of schizophrenia, typically 
adolescence, is gaining recognition as a critical period for the initiation of smoking 
behaviors that may be precursors to or exacerbate the symptoms of schizophrenia. The 
ultimate goal of this research was to identify pharmacological targets for facilitating 
smoking cessation in schizophrenia. 
Diagnoses and Characteristics of Schizophrenia
Schizophrenia effects approximately 1% of the population nationwide, with a 
slight increase in occurrence in males versus females [1,3,4]. Symptoms of 
9schizophrenia are dynamic in that they change over the course of the disease and over 
the lifetime of the patient. The symptoms of schizophrenia are typically classified into 
positive and negative categories. Positive symptoms include delusions, auditory and 
sensory hallucinations, and disorganized speech [5]. Negative symptoms include 
cognitive deficits in learning, memory, and attention, flattened affect (lack of expression 
of emotions), decreased motivation (anhedonia), and withdrawal from social situations 
[6]. There are 3 distinct and well defined stages of the disease that are not only 
important in diagnosing the disease but may also be important in treatment options for 
individuals suffering from schizophrenia and schizophrenia-like symptoms. The first 
stage is the prodromal stage, which typically occurs one year before diagnosis of the 
disease. Characteristics of the prodromal stage include withdrawal from social 
situations, decreased motivation (anhedonia), and flattened affect (reduced emotions) 
[5]. The second stage is the active stage, characterized by delusions, hallucinations, 
and psychotic episodes. The third stage is the residual stage in which symptomology 
commonly mimics the prodromal stage. Symptoms may be recognized as often as early 
childhood, while the disorder does not fully manifest until late adolescence [5]. 
Etiology of Schizophrenia
The etiology of schizophrenia has not been determined and several hypotheses
describing aberrant neurotransmission in the brain are currently being investigated. One 
common thread in the overall function of the schizophrenic brain implies involvement of 
the DA system. In the late 1970s it was shown in postmortem brain tissue that 
nonmedicated schizophrenic humans had an increase in DA receptor sensitivity in 
several brain areas that differed significantly from control subjects [7]. The discovery of 
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the typical antipsychotics chlorpromazine in the mid 1950s and later haloperidol in the 
1960s, which are both potent DA D2 receptor antagonists, led to targeting of the DA D2
receptor for treatment of schizophrenia. Currently, effective pharmacological treatment 
for the symptoms of schizophrenia relies on the drug’s affinity for the D2 receptor, and 
all current antipsychotic medications block the dopamine D2 receptor with some affinity 
[8-10]. It is clear from past research that increased DA D2 receptor function is implicated 
in the pathophysiology of schizophrenia, which was the primary focus for this study. 
Over the past 30 years extensive research in the field of psychoses and 
schizophrenia has focused on DA function and dysfunction in the brain as it compares 
to neurotransmission in normal humans [7, 11, 12]. Early research suggested 
differences in limbic forebrain and striatal structures of the brain and decreased cortical 
volume [13]. Clinical observations pointed toward a role of DA in the psychotic brain 
because of 2 main findings. The first finding showed that acute, high doses of 
amphetamine were able to induce a schizophrenia-like state in normal individuals, 
suggesting increased DA function in schizophrenia [14]. The second finding revealed 
that effective neuroleptic medications had strong DA receptor antagonist effects on the 
brain [14]. Although the etiology of the schizophrenia remains inconclusive, knowledge 
of altered DA function is a major contributor to the understanding of the disorder in 
humans.
In addition to the role of DA function in schizophrenia, glutamate function in the 
brain has also been implicated in the pathophysiology of schizophrenia. This hypothesis 
suggests that the pathophysiology of schizophrenia may be due to glutamate 
hypofunction via decreased activation of the N-methyl-D-aspartate (NMDA) receptor in 
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this disorder [15, 16]. Glutamate and one of its receptor subtypes, the NMDA receptor, 
can directly and indirectly influence DA function in the brain [17]. Glutamate influences 
dopamine signaling in the pathways that connect the striatum and nucleus accumbens 
(Acb), and this circuitry controls learning, memory, and integration of cognition and 
motivation [18]. NMDA receptor antagonists such as phencyclidine (PCP) and ketamine 
decrease glutamate function [19] and secondarily increase DA function, which causes 
schizophrenia-like symptoms in humans [16]. Decreased gene expression for NMDA 
receptors has been shown in postmortem brain tissue of schizophrenic humans as 
compared to normal humans [20]. Administration of NMDA receptor antagonists to 
schizophrenics exacerbates preexisting symptoms and causes schizophrenia-like 
symptoms in normal humans. However, unlike DA receptor-targeted therapies for 
schizophrenia, glutamate receptor agonists fail to reduce symptoms of schizophrenia in 
humans. 
Drug Stimulation of the Mesolimbic DA System
Dopaminergic cell bodies located in the ventral tegmental area [VTA] send major 
projections to brain areas including the basal ganglia, amygdala, and nucleus 
accumbens (Acb), and minor projections to the olfactory tubercle, hippocampus, and 
cerebral cortex [14]. An important dopamine projection that plays a major role in positive 
reinforcement and drug addiction originates from DA cell bodies in the VTA and projects 
to the nucleus accumbens and frontal cortex. The projection from the VTA to the Acb
has been hypothesized to be the primary drug reinforcement pathway in the brain and is 
referred to as the mesolimbic dopamine pathway [21]. Behaviorally, stimulation of this 
pathway by abusive drugs increases self-administration, which is an accepted model of 
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drug seeking behavior in which the animal remotely administers a drug via an 
intravenous line or intracerebroventricular injection [22]; and locomotor activity, which is 
marked by increased locomotion in response to administration of a stimulant, and 
serves as a mesurement for stimulant properties of drugs [23]. Additionally, conditioned 
place preference (CPP) serves as another measure for drug addiction by pairing the 
drug with a context in which the animal develops an association between a drug, such 
as nicotine, and the context in which the drug was administered [24]. Intra-cranial 
administration of DA receptor antagonists to the VTA or Acb blocks self-administration 
of reinforcing drugs, such as nicotine, cocaine, and amphetamine [24-26], which 
suggests participation of the mesolimbic DA pathway in reinforcement. Dopamine 
receptor antagonists block increases in locomotor activity to drugs of abuse, such as 
nicotine, and the associative effects of drugs that are mediated by the mesolimbic DA
pathway [27-29]. Additionally, animals electrically self-stimulate the mesolimbic DA 
pathway via an electrode implanted in brain areas that modulate reward, such as the 
Acb and DS [30, 31]. Thus, it is apparent that the mesolimbic dopamine pathway is 
involved in mediating reinforcing effects of stimuli, and altered function of the 
mesolimbic pathway in schizophrenia may affect the reward potential of stimuli that act 
on the DA system. 
Mechanisms of Drug Reward in the Brain
Stimulation of the mesolimbic pathway, which consists of major DA projections 
from the VTA to the Acb, leads to increased release of DA in the Acb [32, 33]. Increased 
DA function in the Acb has been shown to contribute to the rewarding and motivating 
properties of drugs of abuse, such as nicotine [34], and these findings will be discussed 
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briefly. Behaviorally, the activating and addictive properties of a given substance can be 
evaluated by increased locomotor sensitization, increased conditioned place 
preference, and increased self-administration of the drug using preclinical models. 
These behavioral tasks, mediated by increases in DA activity, are a result of increased 
DA release in the nucleus accumbens [Acb] [32, 33]. In contrast, decreased DA levels in 
this pathway lead to anhedonia, which can result from withdrawal from drugs of abuse 
or from a lack of DA function in the mesolimbic DA circuitry [35, 36].  It is apparent that
the rewarding properties of drugs of abuse stem from activation of the mesolimbic 
dopamine system, resulting in increases in the dopamine response and pleasurable 
feelings that are associated with drug reward. Stimulation of DA neurons by 
administration of DA agonists leads to increased release of DA from the Acb; a 
relationship that is required in order to establish the rewarding effects of stimuli [37-39]. 
The discontinuation of drug use or withdrawal causes a dopamine-depleted state, which 
is used as a general anhedonia model [35, 40]. Behavioral studies have shown
dopamine depleted animals exhibit higher self-administration of drugs of abuse than 
subjects with normal levels of dopamine, suggesting involvement of dopaminergic 
systems in the Acb and the reinforcing effects of addictive drugs [36]. Repeated 
exposure to DA agonists results in a heightened response of the DA system due to use 
of the drug over time, verified behaviorally by locomotor sensitization [41], and 
electrochemically by intracranial self-stimulation (ICSS) studies involving reward 
circuitry [32]. Behavioral studies have shown, for example, that sensitization to 
psychostimulants and other drugs of abuse is a causal link to repeated drug use [41]. 
Over time, repeated exposures to the same dose of a psychostimulant result in 
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increased behavioral response to the drug, also known as locomotor sensitization, or 
reverse tolerance, and this enhanced response is considered to be an indication of the 
addictive properties of stimuli, such as nicotine [41, 42]. 
Nicotine Action in the Brain
Nicotine is a member of the psychostimulant class of drugs [43]. Upon entering 
the blood stream, nicotine rapidly crosses the blood brain barrier and enters the brain 
where it acts as an agonist at endogenous nicotine acetylcholine receptors (nAChRs), 
which are located on many types of neurons in the brain, including, but not limited to 
acetylcholine, DA, and glutamate neurons [43]. To date, 17 genes encoding nAChRs 
have been identified in the brain and peripheral nervous system [44]. Nicotinic receptors 
are made up of a combination of alpha and beta subunits. Currently, 12 different 
subunits exist, consisting of 9 alpha (α2-α10) and 3 beta (β2-β4) subunits that have 
been identified and cloned in humans [44]. Nicotine acts on receptors in both the 
peripheral and central nervous system, with its greatest affinity for the receptors located 
in the central nervous system [45]. Two primary subtypes exist in the brain: the α7
nAChR and the α4β2 nAChR. The latter contribute greater than 90% of the high affinity 
binding sites for nicotine in the rat brain [46, 47].  
The amount of nicotine absorbed by the body depends on the route of 
administration (smoking, chewing gum, chewing tobacco, and snuff) and the dose of 
nicotine administered, which correlates with nicotine’s effects on subsequent nAChR 
activation in the brain [46]. Endogenously, nAChRs bind to acetylcholine; however, 
nAChRs are presynaptically located on dopaminergic as well as glutamatergic neurons 
in the striatum and nucleus accumbens [48]. When these receptors are bound by 
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nicotine, calcium enters the presynaptic terminal and acts to increase the release of 
dopamine [48]. Increased DA release is indirectly affected by stimulation of α7 nAChRs, 
which are localized on glutamatergic neurons. When nAChRs on glutamate neurons are 
activated, glutamate is released and acts on DA neurons, which subsequently leads to 
DA release [49]. DA release is directly affected by stimulation of α4β2 nAChRs, which 
are localized directly on dopaminergic neurons [48]. Additionally, nAChRs are present in 
the VTA, where their activation leads to excitation of DA neurons [50]. Thus, nicotine’s 
agonist action produces either direct or indirect increases in dopaminergic function in 
brain areas of drug reward. 
Nicotine Use in Schizophrenia
Comorbid drug use occurs with many psychological disorders including 
schizophrenia [51]. Findings have shown that the vast majority of schizophrenics are 
heavy smokers, and schizophrenics smoke 3 to 4 times more than the general smoking 
population [52]. And, nicotine is the most highly used addictive substance in 
schizophrenics. Schizophrenic smokers, through differences in inhalation patterns,
extract more nicotine from a cigarette than do nonschizophrenic smokers, possibly 
increasing nicotine addiction [53]. Studies have shown that schizophrenics have 
increased serum levels of cotinine, a metabolite of nicotine, versus nonschizophrenic 
smokers [54]. Increased metabolites found in the serum of schizophrenics, which may 
again be due to an alteration in inhalation patterns, as compared to normal human 
smokers, that allows for larger amounts of nicotine to be extracted from each cigarette 
[54]. From a mechanistic standpoint, it has been suggested that a critical mediator of 
nicotine’s effects in schizophrenia may be due to its action at the low affinity α7 
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receptor. This idea stems from analyses of postmortem brain tissues from human 
schizophrenics that have reported a significant decrease in hippocampal α7 nAChRs, 
which may possibly underlie cognitive impairment in this disorder [55, 56]. Because 
hippocampal α7 nAChRs are down-regulated in postmortem tissue in humans, Martin 
and Freedman have hypothesized nicotine use as a form of self-medication for cognitive 
impairment, possibly via alleviation of deficits in sensorimotor gating [57]. From a 
behavioral standpoint, increased nicotine action at the low affinity α7 receptor may 
alleviate cognitive deficits associated with low α7 binding in the hippocampus of 
schizophrenic humans [58]. Increased nicotine binding may provide the individual with 
increased selective attention, as shown by attenuation of PPI deficits in humans, and 
possibly alleviation of sensory dysfunction [54, 58, 59]. 
Consequences of Nicotine Use in Schizophrenia
Nicotine dependence in schizophrenics has been shown to decrease overall 
quality of life and shorten the lifespan of smoking schizophrenics by 20% [60]. For 
example, smoking may reduce blood levels of certain antipsychotic agents [45-47]. As a 
result, individuals with schizophrenia who smoke may require increased doses of 
antipsychotic medication [47, 48] that would lead to variable plasma concentrations of 
antipsychotic meds [49].  A known side effect of long-term antipsychotic medication 
administration, tardive dyskinesia (repetitive, involuntary body movements) has been 
linked to smoking behaviors in schizophrenics [45 51], which may result from higher 
doses of antipsychotics required in these patients [52]. Interestingly, research has 
shown that smoking behaviors are decreased in schizophrenics administered 
antipsychotic drugs than those who are not medicated [31]. In order to further examine 
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the relationship between antipsychotic medication and nicotine use on symptoms of 
schizophrenia, we first examined the effects of nicotine on behavior and neuronal 
adaptations in a rodent model of schizophrenia. 
Modeling Psychoses in Rodents
These experiments focused on findings using a rodent model of schizophrenia.
Rodent models of neurological disease are important and useful tools for studying 
components of specific diseases; however, modeling all aspects of a disorder is nearly 
impossible. Animal models can be useful for studying the etiology of a disorder, 
comparing treatments for a particular disease, or for development and discovery of new 
and more effective treatments for neurological disorders [61]. One disadvantage in 
using animal models is that they may not be able to predict the lifetime progression of a 
disorder. In most cases, animal models of neurological disease and dysfunction are 
used to model one or a few aspects of the disorder, whether they are behavioral, 
neurochemical, or neuropathological [62]. Findings from animals may be informative 
about the contribution of said behavioral or neurochemical abnormalites to the disease 
or disorder even if the entire disorder is not modeled in the animal [63].  Additionally, 
high genetic homology between rodents and humans allows for translation from animal 
to human. Additionally, this strengthens use of animal models for testing antipsychotic
drugs, therefore supporting the use of animals to model neurological disease [64].
Pharmacological advances have increased management of schizophrenia in 
humans suffering from the disorder; however, the functional cause of the disease has 
yet to be determined. By modeling specific aspects of psychiatric disorders in an animal 
model, we are more likely to be able to understand the connection between the 
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neurological basis and the associated behavioral manifestations of the disorder [62].  
Currently, over 60 rodent models of schizophrenia exist and are based on alterations in 
neurotransmitter function as well as various types of adult and neonatal brain lesions.
Criteria for Modeling Psychosis in Rodents
Attempts at modeling behavioral disorders in rodents have been made for 
decades, and few models, if any, encompass the full extent of its intended disorder. 
Because it is nearly impossible to model all aspects of a disorder, criteria for modeling 
disorders in animals have been suggested; however, to date, no stringent set of rules 
for modeling disorders in animals has been accepted. This is especially important with 
the translational focus that has developed at the National Institutes of Health (NIH). In 
1977 McKinney proposed 4 criteria specific for validating animal models of disorder, as 
described by Tordjman and colleagues [62]. These criteria included similarity in
behavior, inductive conditions, neurobiological mechanisms, and response to 
pharmacological treatment comparable to those seen in humans presenting the specific 
disorder [62]. Later, Robbins and Sahakian suggested 3 criteria, which were defined as 
face validity (behavioral similarity), construct validity (etiology or neurobiological 
similarities), and predictive validity (the ability to identify therapeutic medications for 
treatment of a disorder) to the actual human disorder [62, 66]. Finally, yet a third set of 
criteria for modeling human disorders in animals has been proposed that places each 
model into 3 distinct categories; homologous (face, construct, and etiologic validity), 
isomorphic (face validity), and predictive (predictive validity) [62]. Homologous models 
are rare and require identical symptomology as compared to humans over the time 
course of the disorder. As a result, many models displaying partial homology for a 
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disorder are used currently, such as those involving brain lesions. A model may be 
considered isomorphic if the animal displays identical symptoms to the human disorder, 
but the etiology of the disorder in the animal model and humans differ. One example of 
isomorphic modeling would be an animal model in which the human symptoms 
spontaneously occur, such as the spontaneously hypertensive rat, which has been used 
as a rodent model of Attention-Deficit Hyperactivity Disorder (ADHD). Predictive models 
can be used to screen the effectiveness of pharmacological treatments for a disorder 
[62]. Currently, there is no standard set of criteria for modeling disorders; however, each 
model has primary strengths and weaknesses. Several models exemplifying face, 
construct, or predictive validity will be discussed, including the neonatal quinpirole 
model that is the focus of the current study. 
Because schizophrenia is known to result in a number of neurobiological 
abnormalities, there is no animal model that can effectively mimic all aspects of the 
disease process. Instead, individual aspects of the disease that parallel human 
symptoms and neurological abnormalities are modeled in an attempt to more fully 
understand the dysregulation that leads to psychoses [66]. A neural hallmark of 
schizophrenia is an increase in dopamine D2 sensitivity, as all antipsychotics block the 
dopamine D2 receptor with some affinity [67]. However, it is known that schizophrenia is 
a multi-faceted disorder with disruptions in a number of neurotransmitter systems. On 
the other hand, it is not known whether the changes in these neurotransmitter systems 
result from increases in D2 sensitivity. This project is focused on a rodent model of 
psychosis, most applicable to schizophrenia, which was developed in Dr. Richard 
Kostrzewa’s laboratory.  In this model, quinpirole, a DA D2/D3 agonist, is given 
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neonatally resulting in an increase in dopamine D2-like receptor sensitivity throughout 
the animal’s lifetime without resulting in an increase in the number of D2 receptors [68]. 
The neonatal quinpirole model of schizophrenia is useful for assessing this disorder in 
rodents because it is a developmental model that is based on persistent DA receptor 
supersensitivity, unlike other models of schizophrenia, as detailed below. 
Past Rodent Models of Schizophrenia
As previously stated, there are over 60 different animal models of schizophrenia 
in existence, and these models are derived in a variety of ways. Many models rely on a 
genetic mutation [64], alteration in prenatal development, such as maternal exposure to 
influenza [69] or other neuropathology, such as maternal separation and social isolation 
[70], all of which are consistent with schizophrenia. However, there are 2 types of 
models that are most often used when studying schizophrenia in rodents, which include 
acute drug exposure and neonatal lesions. These models and their strengths and 
weaknesses are described below.  
The strength of past models is that they mimic positive and negative symptoms 
of schizophrenia in normal humans, and they alter neurotransmission in a fashion 
similar to the abnormalities observed in schizophrenia in humans. Administration of 
PCP or amphetamine results in psychotic-like symptoms in normal humans [71-73]; 
however major weaknesses exist in these models. PCP acts as an NMDA receptor 
antagonist, and a partial DA agonist, whereas amphetamine acts in part as a dopamine 
agonist. Acute, high dose administration of PCP or amphetamine results in changes in 
brain pharmacology that are consistent with schizophrenia; however these models do 
not produce a developmental change in the individual as is observed in human 
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schizophrenia [74]. Second, the PCP and amphetamine models do not produce long 
lasting neuronal adaptations that lead to psychotic symptoms. 
Many models are based on lesions of specific brain areas to produce behaviors 
that parallel those exhibited by human schizophrenics. The most often used and 
validated rodent model of schizophrenia, the neonatal ventral hippocampal lesion 
model, relies on cell death in the ventral hippocampus to produce increased locomotor 
activity and changes in social interaction in rodents [75, 76]. This model was originally 
developed by Lipska and Weinberger [76, 77] and is based on hippocampal 
dysfunction, because schizophrenics show a significant increase in size of the lateral 
ventricles and significantly smaller hippocampi than normal subjects [78]. In this model, 
neonatal ventral hippocampal lesions are performed using ibotenic acid infusions on 
postnatal day 7, which results in abnormalities of numerous dopamine-related behaviors 
specific to schizophrenia in adulthood. For example, rats with neonatal lesions exhibit 
greater behavioral sensitization to cocaine and nicotine than control subjects, 
suggesting a higher susceptibility to psychostimulant abuse [79, 80]. Additionally, this 
model mimics the effects of changes in mRNA of DA and GABA markers in various 
regions of the brain that are also seen in human schizophrenics [81]. The neonatal 
lesion has shown a significant reduction in expression of dopamine transporter (DAT)
mRNA and tyrosine hydroxylase (an enzyme involved in DA production) gene 
expression in the substantia nigra and VTA as adults. However, adult lesions do not 
show changes in expression of DAT or other DA related genes [82]. Behaviorally, 
neonatal hippocampal lesions produce several behavioral deficits consistent with 
schizophrenia, including hyperlocomotion, prepulse inhibition deficits, social withdrawal 
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and isolation [75], as well as cognitive impairment [83]. It is important to reiterate that 
there is no evidence of cell death in the hippocampus in human schizophrenics [78, 79, 
84]; therefore, there are some weaknesses in this model that may not be accurate 
relative to the neuropathology in schizophrenia.  
A Novel Rodent Model of Psychosis
Studies from a collaborating laboratory have shown that repeated quinpirole 
administration during neonatal development in rats produces a marked 
supersensitization of dopamine D2-like receptors [2]. Increased D2 receptor sensitivity is 
consistent with human schizophrenia [7], and all antipsychotic drugs target this receptor 
family with some affinity. Neonatal quinpirole treatment leads to D2 supersensitization 
without changing DA receptor number, which is also consistent with human 
schizophrenia, as there has been no report of upregulation in DA D2 receptors in 
humans [85]. Additionally, neonatal quinpirole treatment in rats results in
supersensitization of the D2/D3 receptor that lasts throughout the animal’s lifetime [2, 
85]. Dopamine D2 supersensitization is shown behaviorally through hyperlocomotion, 
increased vertical rearing, increased horizontal activity, and increased yawning in 
response to acute quinpirole treatment and dopamine-related behaviors [86]. 
Validation of the Neonatal Quinpirole Model of Schizophrenia
There are a number of consistencies between findings in schizophrenia in 
humans and the neonatal quinpirole model. Certain physical aspects of schizophrenia 
suggest that the disease is not due to neuropathology, or cell death in the brain, but due 
to a neurodevelopmental abnormality [74]. This model mimics developmental changes 
in the dopamine system present in human schizophrenia because neonatal quinpirole 
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treatment affects developmental stages of dopaminergic pathways. Findings using the 
neonatal quinpirole model have revealed several key behavioral and neurochemical 
deficits that are also observed in schizophrenics, which are detailed below. 
Pharmacological Validation 
A key hallmark of any rodent model of a disorder is that treatments commonly 
used to alleviate behavioral or neurochemical abnormalities in that disorder in humans 
have also been found to be effective in the rodent model. This laboratory reported that 
olanzapine treatment given twice daily for one month in adulthood alleviated cognitive 
deficits in Morris water maze performance produced by neonatal quinpirole treatment 
[87] consistent with human data [88]. Importantly, olanzapine alleviated the increase in 
yawning behavior, which is a D2/D3 receptor mediated event, in response to acute 
quinpirole in this model [87]. This demonstrates that increased D2 sensitivity is likely 
responsible for these behavioral effects, and antipsychotic treatments are effective in 
alleviating these effects. In vitro analyses showed that decreases in hippocampal brain-
derived neurotrophic factor (BDNF) and nerve growth factor (NGF) produced by 
neonatal quinpirole were alleviated by olanzapine to control levels after an 8-day 
washout [87], also consistent with findings of this drug treatment in humans [89]. 
Altered Expression of Neurotrophic Factors in the Brain
Neonatal quinpirole treatments produce neurochemical abnormalities in 
adulthood that are consistent with observations made in human schizophrenics. Our
laboratory has shown that neonatal quinpirole treatment produced significant decreases 
of hippocampal choline acetyltransferase (ChAT), BDNF, and NGF protein content 
compared to saline controls in both early postweanling and adult rats [90, 91]. 
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Additionally, polymerase chain reaction (PCR) analyses from this laboratory have 
shown a significant decrease of NGF, BDNF, and ChAT expression in the hippocampus 
of animals neonatally treated with quinpirole. Human schizophrenics also demonstrate
significant decreases in NGF [89] and BDNF protein [92, 93] as well as significant 
reductions in ChAT expression in the hippocampus [94, 95], Acb, and pontine 
tegmentum [92, 93], which are all consistent with this model.
Effects of Psychostimulants
Imaging studies have shown that amphetamine administration produces a large 
increase in dopamine overflow in the dorsal striatum of schizophrenics [96-98]. This lab 
and collaborators have shown that adult rats neonatally treated with quinpirole 
demonstrate more robust locomotor sensitization in response to adulthood 
amphetamine treatment [99], which also leads to a 500% increase in the release of 
striatal and accumbal dopamine overflow [100]. 
Deficits in RGS9 Protein in the Brain
RGS9 is a regulator of G-protein signaling at the dopamine D2 receptor and 
RGS9 has been shown to be responsible for cessation of dopamine receptor activation 
due to action of a dopamine agonist. Postmortem analyses of schizophrenics have 
shown significant decreases of hippocampal Rgs9 expression [101, 102]. Decreases in 
RGS9 protein activity are common in cases of dopaminergic hyperactivity [101]. We 
have shown through in situ hybridization that neonatal quinpirole treatment results in a 
robust significant decrease of Rgs9 expression in the Acb, striatum, and frontal cortex 
[103]. 
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Deficits in Prepulse Inhibition (PPI) 
PPI provides an operational measure of sensorimotor gating, and has been 
shown across a number of studies to be disrupted in schizophrenia [104, 105]. PPI of 
the startle response refers to an attenuated response to a strong stimulus (pulse) when
this is preceded shortly by a weak, nonstartling stimulus (prepulse). In fact, deficits in 
PPI have been suggested to be the most consistent behavioral hallmark of 
schizophrenia and to be the underlying mechanism of cognitive impairment in the 
disorder [106].  Neonatal quinpirole treatments have been shown to produce deficits in 
auditory sensorimotor gating using PPI. Unpublished data from our laboratory have
shown that adult rats given neonatal quinpirole treatment demonstrated PPI deficits as 
compared to controls.   
Cognitive Impairments
Neonatal quinpirole treatments have been shown to produce cognitive 
impairment that persists into adulthood [108]. Cognitive impairment is present in 
schizophrenia, and it has also been suggested that cognitive impairment is a core 
feature of the disorder [106]. This lab has shown in several studies that neonatal 
quinpirole treatment results in cognitive impairment in early postweanlings [92] and in 
adulthood [90, 107-109].
Dopamine, Schizophrenia, and Addiction: A Common Tie?
Interestingly, addiction to certain drugs, such as alcohol and amphetamine, as 
well as prenatal exposure to particular drugs, such as cocaine, has been shown to 
increase sensitivity of dopamine receptors. Addiction to nicotine is thought to be a result 
of nicotine’s effects on the dopamine system [110]. The discovery of changes in 
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dopamine receptor function as a result of antipsychotic medication points to a shared 
underlying mechanism in both drug addiction and psychoses [111, 112]. A significantly
higher incidence of psychostimulant abuse exists in the schizophrenic population as 
compared to the general population [59]. It has been estimated that up to 90% of the 
schizophrenic population smokes cigarettes, as compared to only 20% of the general 
population [55] and up to 77% of schizophrenics begin smoking before diagnosis of the 
disorder [112, 113]. Human schizophrenics exhibit differences in smoking patterns, rate 
of smoking, and inhalation patterns than normal smokers.
Schizophrenic smokers and normal smokers report similar reasons for nicotine 
use, including reduction of stress, anxiety, and agitation, and they report similar 
withdrawal symptoms. Comparatively, schizophrenics smoke more than normal 
humans, suggesting an increased motivation to smoke in the schizophrenic population 
[114]. Differences in smoking behaviors between these 2 populations led to the notion 
that schizophrenic smokers are using nicotine as a form of self-medication. As 
mentioned above, one possible explanation for using nicotine as a form of self-
medication is to alleviate sensory gating abnormalities and attention deficits caused by 
the disorder [58, 113]. Additionally, some patients report an increase of psychiatric 
symptoms during withdrawal [35, 115], and these withdrawal symptoms are especially 
increased with antismoking agents [116]. Research has shown that use of certain 
neuroleptics causes an increase in cigarette smoking in schizophrenic patients due to 
dopamine D2 receptor blockade. For example, the typical antipsychotic haloperidol, 
which is an especially potent dopamine D2 receptor antagonist, was reported to 
increase smoking in normal nonschizophrenic smokers as compared to baseline [117]. 
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It is believed that this is due to a decrease in function of dopamine receptor sites, 
namely the D2 receptor, reinforcing nicotine intake in order to compensate for a lack of 
dopamine-related reward [118]. 
Reduction of Anhedonia: Self-Medicating With Nicotine?
One possible hypothesis for increased smoking in schizophrenia is that smoking 
is used to self-medicate a number of different symptoms. For example, a diminished 
reward system, due to neuroleptic antagonism of the DA system, has been suggested 
as the cause of apathy and lack of motivation characteristic of negative symptoms in 
schizophrenia [119]. Nicotine's ability to augment dopamine release is suggested to be 
a potential physiological antagonist to negative symptoms that may underlie the high 
prevalence of smoking in schizophrenics [120]. Nicotine alleviates negative symptoms,
cognitive impairment, and behavioral abnormalities associated with schizophrenia [118]. 
Nicotine also reportedly reduces known side effects of antipsychotic treatment, such as 
lethargy and flattened affect, in treated individuals [113]. Corroborating the self-
medication hypothesis of nicotine in schizophrenia, imaging studies in schizophrenics 
demonstrate a sensitized dopaminergic response to nicotine in brain reward areas [97], 
in agreement with past work on amphetamine and its effects on the dopamine system in 
schizophrenics [98]. In sum, increased DA activity, which mediates positive 
reinforcement, is the basis of this self-medication hypothesis.
Alongside the hypothesis of nicotine self-medication, it is also suggested that 
higher levels of smoking in schizophrenia may be attributed to other aspects of the 
disorder, such as personality traits. In general, smokers are more likely to exhibit
neurotic traits and social alienation and less likely to exhibit achievement traits and 
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strong socioeconomic status [121]. Schizophrenics also fit this personality profile, with 
negative symptoms producing a general flat affect, and positive symptoms increasing 
paranoia and social alienation [4]. Together, this evidence strengthens the hypothesis of 
nicotine self-medication and an increased propensity to smoke in the schizophrenic 
population. 
Effects of Nicotine on Rodent Behaviors
Increased dopamine release induced by nicotine has been hypothesized to play 
an important role in the reinforcing and locomotor stimulation effects of nicotine. For 
example, nicotine has been shown to increase locomotor sensitization when locally 
injected into the VTA [122]. The ability of nicotine to induce increased locomotion and 
also conditioned place preference [125] suggests that nicotine has psychostimulant and 
addictive properties [126]. The increase in behavioral response to nicotine has been 
shown through increased locomotion, increased vertical rearing behavior, as well as 
dopaminergic related behaviors such paw treading and grooming [38, 126, 127]. It is 
understood that other neurotransmitter systems are also involved in this phenomenon, 
but this may be attributed to modulation of other systems due to increased release of 
dopamine in the VTA-Acb pathway [121].  
Adolescence: Psychostimulant Abuse and Psychoses
As suggested in the literature, smoking behaviors tend to begin in adolescence
[128]. Although the diagnosis of schizophrenia does not occur until the late 20s, often 
the early phase of the disorder and occurrence of symptoms begins in adolescence [5]. 
Smoking in adolescence has been attributed to the severity of schizophrenia and have 
also been implicated as a precursor to this disease [1,129].
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The DSM-IV states that the onset of schizophrenia typically occurs between the 
late teens and the mid-30s, thus, adolescent schizophrenia has not been adequately
studied. It is apparent that some aspects of the disorder are observed during the early 
adolescent period before an individual presents with a full spectrum of schizophrenic
symptoms [129], and schizophrenia is now considered to be a neurodevelopmental 
disorder [74] with its pathogenesis putatively stretching back to gestation and early 
childhood [130]. The use and abuse of alcohol, marijuana, psychostimulants, and other 
drugs are commonly found to be comorbid with psychiatric conditions in adolescents 
[131]. Weiser and colleagues [1] reported that in a large population of adolescents 
(14,000+), approximately 28.4% smoked at least one cigarette a day. Over a 4-16 year 
follow-up, it was found that adolescent smokers were at greater risk for schizophrenia, 
and the number of cigarettes smoked was associated with a significantly increased risk 
for schizophrenia. Compared to nonsmokers, adolescents who smoked at least 10 
cigarettes/day were 2.28 times as likely to be hospitalized for schizophrenia than 
nonsmokers. Baker and colleagues [132] also reported that individuals diagnosed with 
psychosis began smoking daily at about 18 years of age, had higher levels of nicotine 
dependence, and demonstrated concurrent hazardous use of other drugs at a younger 
age. 
One explanation for the increased propensity to use drugs in collaboration with 
the early emergence of symptoms leading to diagnosis of a disorder, such as 
schizophrenia, is that the adolescence period of development involves a rapidly 
changing environment in the brain in which the DA system development is highly 
vulnerable to changes induced by stimuli, such as nicotine [133]. During adolescence, 
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the DA system is dynamic, and this time period is marked by rapid changes in DA 
pathways [133]. The precise definition of adolescence has been debated in the literature
but is described behaviorally by increased social behaviors and interactions as well as 
increased likelihood to engage in risky behaviors [134]. During this developmental 
period, adolescents are more vulnerable to the addictive properties of drugs of abuse, 
especially psychostimulants such as nicotine [127]. Recently, it has been suggested 
that psychostimulant abuse in adolescence may lead to sensitivity of the DA system. 
Subsequently, this may lead to manifestation of schizophrenia in adulthood [1]. It is also 
likely that adolescent psychostimulant abuse preceding diagnosis of disorder is an 
effect of the early stages of schizophrenia [127, 134, 135]. Sex differences in the effects 
of psychostimulants on adult rodents and humans have been shown [136, 137]; 
however, less is known about the effects on adolescent rodents and humans. Because 
adolescence is a crucial time for the development of neuronal pathways, especially DA 
pathways [133], it is important to emphasize the effects of psychostimulant abuse on 
neuronal adaptations in this population. 
Neuronal Markers for Synaptic Plasticity
Drug use and drug addiction lead to changes in synaptic plasticity in the brain. 
Synaptic plasticity can be defined as a change in the communication between neurons 
in response to increases and decreases in use of a particular synaptic pathway, 
typically due to stimulation of the pathway via experience, learning, or the influence of 
drugs. The best-described mechanism of increased synaptic plasticity is NMDA receptor 
mediated, which leads to depolarization of the cell and subsequent calcium influx [138]. 
Calcium influx leads to initiation of the second mechanism, involving a signaling 
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cascade controlled by a second messenger system, leads to gene transcription and 
ultimately dendritic growth and changes in synaptic strength [138]. Under normal 
circumstances, bi-directional NMDA receptor activity contributes to homeostatic 
plasticity in the brain [138]. Homeostatic levels of NMDA receptor activation are altered 
by neuronal activation such as experience and drug abuse [139, 140]. Drugs of abuse 
can impact synaptic plasticity by increasing neurotransmission and expression of
neurotrophic factors, such as BDNF [141]. Drugs of abuse also lead to increased gene 
expression mediated by activation of transcription factors such as cyclic-AMP response 
element binding protein (CREB) [142, 143]. 
Neurotrophic factors and transcription factors that regulate synaptic growth and 
plasticity are important in the pathology of schizophrenia and comorbid nicotine use 
mechanisms for several reasons. First, neurotransmitters and transcription factors 
contribute to the growth and maintenance of DA neurons. Second, they influence the 
development of DA neurons that may be crucial in the development of schizophrenia as 
well as increased use of psychostimulants, such as nicotine, in the schizophrenic 
population. Third, exposure to psychostimulants alters the expression of 
neurotransmitters and transcription factors, such as GDNF, NGF, BDNF, and CREB, 
leading to changes in synaptic plasticity [144-146]. 
Effects of Nicotine on Neuronal Markers of Plasticity
Abusive drugs, such as nicotine, lead to widespread changes in cellular activity in 
the brain. Changes in cellular activity in areas in the brain that modulate reward, 
especially the Acb, may serve as a cellular mechanism that underlies the motivation for 
repeated nicotine use [140, 143, 144]. For example, nicotine exposure in adult rats 
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leads to increased dendritic spine length and density in the Acb [147]; however, the 
specific mechanism underlying the connection between nicotine and increased spine 
density in Acb is still unknown [143]. In other brain areas, it has been shown that 
nicotine produces a significant increase in both NGF and BDNF protein in the 
hippocampus and in frontal cortex of adult rats [148]. Other psychostimulants, such as 
cocaine and amphetamine, produce significant increases in BDNF in the nucleus 
accumbens [149], suggesting that other DA agonists, such as nicotine, may also lead to 
changes in markers for synaptic plasticity in the Acb. In fact, one recent study showed 
increased BDNF levels in the Acb of mice treated with nicotine; however changes in 
BDNF and other markers for synaptic plasticity have not been examined in adolescent 
animals or in a rodent model of psychosis [87, 150, 151]. Behavioral studies have 
shown that adolescent and adult male rats exhibit conditioned place preference to 
nicotine [143, 152], which suggests associative properties and mild reinforcing effects of 
nicotine. Nicotine, cocaine, and alcohol induced CPP increases phosphorylated CREB 
levels in reward modulating areas of the brain, such as the lateral hypothalamus and 
VTA [153, 154], suggesting a connection between active drug seeking and plasticity of 
key reward areas in the brain. 
GDNF
Midbrain GDNF, derived in the VTA, is expressed in the Acb and has been 
shown to specifically promote growth and survival of dopamine neurons in cell culture
and is essential for full development of DA neurons [154]. All midbrain dopamine 
neurons express the receptor subunits for GDNF as well as mRNA for GDNF, except for 
the VTA that expresses the same receptor subunits but not mRNA for GDNF [156]. The 
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absence of GDNF mRNA in the VTA is due to retrograde signaling in the VTA and 
several experiments have shown that accumbal derived GDNF is retrogradely 
transported to the VTA and subsequently increases dopaminergic activity in the nucleus 
accumbens [157].  
Developmentally, GDNF is found throughout the central nervous system where it 
promotes growth of dopamine neurons. In cell culture, GDNF stimulates neurite growth 
and differentiation and regulates the genes responsible for expression of TH and the 
dopamine transporter [158]. In the mature brain high levels are found in the nucleus 
accumbens and dorsal striatum where the function of GDNF is to aid in the integrity of 
dopamine neurons, functions, and pathways [155, 159, 160]. Dopamine firing is 
influenced by GDNF signaling, as shown by intra-VTA infusions of GDNF that result in 
increased spontaneous firing of VTA neurons as well as DA neurons [160]. Influence of 
GDNF in the ventral tegmental area as well as on the spontaneous firing of DA neurons 
has lead to the study of GDNF’s role in the actions of drugs of abuse as well as 
addiction.
GDNF and Addiction
GDNF has been suggested to be to be an “anti-addictive” protein because it
reduces drug cravings and reward of abusive substances [157]. Infusion of GDNF into 
the VTA reduces reward and conversely, decreased GDNF increases drug reward and 
cravings, suggesting GDNF as a negative regulator of drug reward [162]. It is important 
to reiterate that drugs of abuse increase dopamine levels in the Acb and altered 
dopamine modulation underlies drug self-administration in animals [163]. Intra-VTA 
infusion of GDNF decreases conditioned place preference [162] for psychostimulants 
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and decreases self-administration of cocaine, ethanol, and sucrose in rats [164]. 
Meanwhile, a decrease in GDNF levels and subsequent signaling of GDNF in the VTA 
leads to increased behavioral sensitization, which is shown to be mediated by the 
nucleus accumbens. This indicates that normal GDNF function requires a feedback 
from the nucleus accumbens to the ventral tegmental area [165, 166]. Administration of 
GDNF into the VTA of mice reduced the rewarding effects of abusive drugs, and 
infusion of an antiaddiction drug, ibogain, into the VTA increases GDNF mRNA and 
protein levels, suggesting a role for GDNF in the addictive properties of drugs [164, 
167]. Exogenous GDNF leads to decreased production of tyrosine hydroxylase and 
deltafosB [168-170], and anti-GDNF antibody administration into the VTA blocks these 
effects. Although there is an apparent relationship between GDNF and addiction, there 
are no known studies analyzing the effects of nicotine on GDNF, and no study has 
examined these factors in adolescence.  
GDNF and Schizophrenia
The apparent role of GDNF in midbrain development and maintenance of DA 
neurons suggests a potential role for GDNF in the pathophysiology of psychosis in 
humans. Although little research has been done regarding a role for GDNF in 
schizophrenia, one study found that healthy human subjects possess a repeat in allele 
frequencies of the GDNF gene that was not found in schizophrenic subjects [171]; 
however, the aforementioned study is inconsistent with previous work showing no 
changes in allele frequencies for GDNF in schizophrenic patients [172]. Increased levels 
of serum GDNF have been reported in euthymic state (normal nondepressive and 
nonmanic state) bipolar patients compared to manic state patients and control subjects 
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[173], and another study showed decreased GDNF serum levels in depressed state and 
manic state patients as compared to control subjects, a deficit that was alleviated by 
pharmacological drug treatment [174], suggesting that GDNF is altered in some forms 
of psychoses and that chronic drug treatment may mask this evidence. Because most 
schizophrenic patients are medicated, altered GDNF levels may be more difficult to 
detect; however, animal models of increased psychoses, such as the neonatal 
quinpirole model may give insight to this potential mechanism.  
cAMP Response Element Binding Protein (CREB)
CREB is a transcription factor that when activated regulates the transcription of 
specific genes. CREB is activated by a second messenger system that triggers an 
intracellular cascade of events that leads to activation of a protein kinase that 
translocates to the nucleus and activates CREB (by phosphorylation), which then binds 
to the CRE (cAMP regulated enhancer) binding site on DNA sequences in the nucleus 
and induces gene transcription [175]. The phosphorylated form of CREB (pCREB) has 
been shown to be necessary for long-term adaptations that lead to synaptic plasticity 
[176]. CREB regulates the transcription of several genes involved in neuroplasticity, 
including BDNF, tyrosine hydroxylase, and several neuropeptides [177]. Like BDNF, 
abusive drugs and stress also increase CREB activity, leading to studies demonstrating 
its importance in both processes. In terms of drug abuse, increased phosphorylated 
CREB levels in the Acb, mediated by exposure to drugs of abuse as well as 
environmental stress, leads to a profound effect on an animal’s responsiveness to 
emotional stimuli [176, 178]. Importantly, viral vector-mediated elevations of CREB 
within the rat Acb reduce the rewarding effects of cocaine and morphine, as well as 
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sucrose [179, 180]. In fact, this CREB phenotype appears to reflect a generalized 
numbing of behavioral responses to emotional stimuli because animals with increased 
CREB function in the Acb also show reduced responses to a wide range of aversive 
conditions [176, 179]. Conversely, reduced CREB activity in the rat Acb, through viral 
vector-mediated expression of the dominant negative mutant mCREB, increases the 
rewarding effects of cocaine, morphine, and sucrose. It has been hypothesized that 
CREB is a key regulator of the reactivity of brain reward circuits that play a role in the 
processing of emotional stimuli [176, 179]. Most relevant to the current experiments, 
Carlezon and colleagues [176] suggest a sustained elevation of CREB activity in the 
Acb results in signs of anhedonia consistent with negative symptoms of schizophrenia. 
Interestingly, postmortem work in mood disorders, including schizophrenia has reported 
increased CREB in the prefrontal cortex [181], but the NAcc has not been analyzed in 
humans. 
pCREB and Addiction
Drugs that increase dopamine function, including nicotine, lead to increased 
phosphorylation of CREB in the striatum, Acb, and VTA of adult animals and adolescent 
rats [143, 182, 183]. Nicotine results in CPP in adult rats and simultaneously, nicotine 
leads to increased pCREB protein levels and increased Fos expression in the VTA, 
Acb, and DS [184]. Additionally, administration of the nAChR antagonist, 
mecamylamine, abolishes increases in pCREB and Fos protein in response to 
conditioned place aversion (CPA) testing in adult rats [143]. In adolescent studies, rats 
with an increased reactivity to novel stimuli showed greater increases in locomotor 
activity due to nicotine exposure, which resulted in increased pCREB levels in the 
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striatum as compared to control adolescent rats [183].  These data suggest that an 
increased preference for nicotine and the increased locomotor activating properties of 
nicotine may lead to long lasting changes in synaptic plasticity in the brain, which could 
be controlled by phosphorylation of CREB.  Importantly, the relationship between 
nicotine and pCREB in the Acb has not been established in schizophrenia. Findings 
may suggest a relationship between nicotine activation of the Acb and changes in 
pCREB in the self-medication hypothesis of nicotine use in schizophrenia. 
The Anatomy of the Nucleus Accumbens and Dorsal Striatum
A brain area central to the rewarding effects of nicotine is the nucleus 
accumbens. Functionally and anatomically the Acb consists of 2 distinct regions: the 
core and shell. The Acb shell has been referred to as an anatomical extension of the 
amygdala and is involved in the motivated response of an organism or individual to a 
stimulus [185].  Acute drug administration in animals leads to increased DA release in 
the Acb shell, but chronic drug exposure in animals leads to a sensitized DA response
from the Acb core [186]. Functionally, the Acb core is innervated by nuclei that process 
motor information, whereas the Acb shell may have a stronger association with the 
limbic system [187]. Anterograde and retrograde tracing studies have shown that the 
most pronounced differences between core and shell projections exist in regard to their 
connections to the hypothalamus and extended amygdala [188]. The core projects 
primarily to the entopeduncular nucleus including a part that invades the lateral 
hypothalamus, the shell projects diffusely throughout the rostrocaudal extent of the 
lateral hypothalamus as well as to the extended amygdala [188]. Histologically, the core 
is similar to the caudate-putamen in the basal ganglia, furthering its relationship to 
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locomotor activity, while the shell represents a transitional zone that seems to 
characterize most of the fringes of the striatal complex, where its interaction with the 
amygdala serves to integrate emotion and action [185, 189, 190]. The Acb core but not 
the shell has been implicated in conditioned dopamine release in psychostimulant 
locomotor sensitization [186], which leads to the importance of analyzing the DA 
response of the Acb core in the locomotor activating effects of nicotine in the neonatal 
quinpirole model.
Also important in the assessment of the psychomotor effects of nicotine and 
other psychostimulants is the DS. This area is responsible for integrating the DA input 
into the Acb while coordinating the effects of afferent information into behavior and 
sensorimotor responses [189]. Communication between the DS and Acb is important for 
the development of drug reinforcement, and function of the DS is necessary for the 
association of drug-paired cues [185]. Past work has shown that inactivation of the Acb 
core or the DS of rats decreases the responding for a cocaine-paired conditioned 
stimulus, demonstrating the importance of the dorsal striatum in the rewarding 
properties of psychostimulants [185]. 
In sum, it appears that there is a developmental change in the DA system of 
schizophrenic humans, leading to abnormal cellular communication. It is apparent that 
there is no single defined mechanism controlling schizophrenia, but rather a 
combination of behavioral and neurochemical abnormalities relative to the known 
symptoms that lead to the disorder. Schizophrenic humans exhibit differences in brain 
morphology, brain plasticity, DA function, and comorbid disorders, in addition to the 
positive and negative symptoms that characterize this group of individuals. To date, 
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there is no known underlying mechanism of the etiology of schizophrenia; however, it is 
apparent that many factors contribute to the aberrations between schizophrenic and 
normal humans. Current literature and knowledge of this disorder largely focuses on 
adulthood aspects of schizophrenia; however, far fewer experiments have focused on 
earlier manifestations of the disorder in humans. In order gain a better perspective on 
the development of schizophrenia over the lifespan of the individual, it is important to 
begin examining the schizophrenia and schizophrenia like symptoms in an adolescent 
model of the disorder.  A better understanding of adolescent manifestations of 
schizophrenia and drug abuse mechanisms may lead to more effective therapeutic 
advancements in treatment and possibly attenuation of the severity of symptoms. This 
study will examine the effects of nicotine on the behaviors and biological markers of 
brain plasticity in the neonatal quinpirole model of psychosis, focusing on the early 
changes that occur during the adolescent period. 
Hypotheses and Purpose of the Current Study
The purpose of the current study was to examine the effects of nicotine on brain 
plasticity markers and locomotor activity in an adolescent rodent model of psychosis. 
Past evidence from this laboratory showed that nicotine administration to adult and 
adolescent rats that were neonatally treated with quinpirole resulted in a more robust 
nicotine sensitization [126, 191]. It has been shown that a sensitized locomotor 
response to a repeated stimulus is a measure of the addictive and rewarding properties 
of a given stimulus. Several studies have shown that adolescent aged humans and 
rodents are reportedly more sensitive to the rewarding properties of drugs of abuse 
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[192], leading to the hypothesis that nicotine administration in adolescent animals will 
also result in a sensitized locomotor response. 
Hypothesis I 
Repeated nicotine administration will result in sex-differences in the sensitized 
locomotor response in adolescent animals in a dose dependent manner that will be 
enhanced by neonatal quinpirole.   
Past data from this and other laboratories have shown that in vivo microdialysis 
of the Acb core and striatum in response to systemic amphetamine administration in 
adult animals neonatally treated with quinpirole leads to an increase in DA overflow 
versus animals given saline [99, 100]. The Acb is known to modulate reward as well as 
motivation, and the Acb core has especially been implicated in assessment of the 
behavioral response to rewarding stimuli [33]. These experiments lead to the hypothesis 
that nicotine administration would lead to increased DA release from the Acb core in 
adolescent animals that were administered nicotine, and that neonatal quinpirole would 
enhance this response. 
Hypothesis II 
It is hypothesized that in vivo microdialysis will result in increase DA overflow 
from the Acb core in response to systemic nicotine versus systemic saline in adolescent 
animals. Additionally, animals neonatally treated with quinpirole and given nicotine in 
adolescence will exhibit the highest accumbal DA response over all other treatment 
groups.  
It has been shown previously that schizophrenic humans exhibit altered neuronal 
communication in the brain, a finding that has been attributed in altered expression and 
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protein levels of several neurotrophic factors and transcription factors, such as BDNF, 
NGF, and CREB [16, 193]. Aberrant expression of these factors has been shown in 
adults; however, there is little to no evidence in adolescent aged humans or rodents. It 
is hypothesized that neonatal quinpirole treatment in rodents will result in altered BDNF, 
GDNF, and pCREB protein levels in the Acb and striatum versus control animals. 
Additionally, these factors will further be influenced by adolescent nicotine 
administration. 
Hypothesis IIIa
Adolescent nicotine treatment will result in increased BDNF protein levels in the 
Acb and striatum and that neonatal quinpirole treatment will enhance this effect. 
Hypothesis IIIb
Adolescent nicotine treatment will result in decreased GDNF protein levels in the 
Acb and striatum and that neonatal quinpirole treatment will enhance this effect. 
Hypothesis IIIc
Neonatal quinpirole treatment will result in an increase in pCREB protein levels 
in the Acb and striatum, which will be attenuated by adolescent nicotine administration.   
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CHAPTER 2
METHODS
Subjects
Adolescent animals were 35 days old and were randomly assigned to drug group
by gender and neonatal treatment. Animals were assigned to drug groups (refer to 
Table 1) as follows (the first drug represents neonatal treatment and the second drug 
represents adolescent drug treatment): Quinpirole-Nicotine (QN), Quinpirole-Saline
(QS), Saline-Nicotine (SN), and Saline-Saline (SS). 
Table 1. Treatment groups for the current study
Gender Neonatal tx Adolescent tx Code
Female Saline Saline FSS
Female Saline Nicotine* FSN
Female Quinpirole Saline FQS
Female Quinpirole Nicotine* FQN
Male Saline Saline MSS
Male Saline Nicotine* MSN
Male Quinpirole Saline MQS
Male Quinpirole Nicotine* MQN
* A dose response curve for nicotine was performed for behavioral sensitization. 
Different groups of animals received 0.3, 0.5, or 0.7mg/kg nicotine during behavioral 
sensitization. 
43
Research Design
For the proposed set of experiments, separate groups of animals were analyzed 
for each experiment. All procedures were performed within animal regulation, as 
approved by the Institutional Animal Care and Use Committee (IACUC) at East 
Tennessee State University. All animals were neonatally treated with either quinpirole or 
saline, and weaned at postnatal day 21. Separate groups of animals were administered 
0.3, 0.5, or 0.7 mg/kg ip. nicotine (free base) injections during sensitization procedures. 
Only male animals that had been sensitized to the 0.5 mg/kg dose of nicotine were used 
for microdialysis and HPLC experiments because this dose produced the most robust 
sensitization curve, as shown in Figure 1 in the results section. Animals that were to be 
used for BDNF, GDNF, and pCREB analysis were only sensitized to the 0.5 mg/kg dose 
of nicotine and did not undergo microdialysis surgery. 
Neonatal Drug Treatment. Animals were given a single daily intraperitoneal (i.p.)
injection of either quinpirole (1mg/kg) or saline from postnatal day 1-21 (P1-21). All 
animals were administered 1mg/kg quinpirole based on body weight and were placed 
back into the home cage after injections. On P21, animals were weaned and socially 
housed (2-3 animals per cage) by gender. 
Habituation to the Locomotor Arena. On P30-32, all animals were habituated to 
the locomotor testing arena. Each animal received an ip. injection of saline in the lower 
left quadrant of the abdomen and was placed in the home cage for 10 minutes before 
being placed in the testing arena. Animals were tested for 3 consecutive trials. This task 
provided a baseline activity measure and habituated the animal to the locomotor 
apparatus. Horizontal activity was measured by Anymaze software. AnyMaze 
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superimposes a grid of lines on to the locomotor arena. Each time the animal crossed 
one of the lines counted as one activity count, which was used as the primary 
dependent measure for behavioral sensitization. 
Locomotor Sensitization. Following habituation, starting on P33, animals were 
given i.p. injections of nicotine tartarate (0.3, 0.5, or 0.7 mg/kg free base) or saline and 
placed back into the home cage until testing.  Ten minutes after each injection, the 
animals were placed in the locomotor arena, and behavior was recorded for 10 minutes 
on each trial and horizontal activity counted was measured by Anymaze software. 
Testing was performed every other day for 16 days in all groups, from P33-49. The 
rationale for administering the drug every other day is based on the sensitization model 
of Pierce and Kalivas [41], which posits for behavioral sensitization to be measured 
properly, a day of no drug treatment must exist in between drug treatment days to allow 
for complete plasma clearance of the drug. 
Guide Cannula Implant Surgical Procedure. For microdialysis, separate male and 
female animals treated with the 0.5 mg/kg nicotine dose (or saline) were analyzed. One 
day after sensitization testing, animals were fully anesthetized (50mg/kg ketamine, 
10mg/kg xylazine, administered i.p. and sterile guide cannulae (Bioanalytical pin probe, 
Lafayette, IN, Part# MD-2200) were unilaterally implanted, using stereotaxic 
measurements. The guide cannulae were placed into the nucleus accumbens  (+1.7mm 
AP, 1.0mm ML, -6.4mm DV, measured from Bregma) and secured in place by 
inserting 3 mounting screws (PlasticsOne), which served to secure a dental acrylic cap. 
The acrylic cap was given ample drying time and incision was closed using sterile 
suture suture and wound clips. Cannulae placement was balanced across subjects 
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between left and right hemispheres to control for laterality effects. Postsurgery, animals 
were monitored during recovery, and, once ambulatory, returned to the home cage. 
Animals were allowed to recover for 2-10 days prior to microdialysis testing. 
Microdialysis Procedure. On the day of microdialysis testing, microdialysis 
probes (2mM) were flushed for 1 h before use (1μl/min flow rate) with artificial 
cerebrospinal fluid (aCSF) (in mM: 145 NaCl, 2.8 KCl, 1.2 MgCl2, 1.2 CaCl2, 0.25 
ascorbic acid, and 5.4 d-glucose, pH 6.5–7.0 adjusted with NaOH). Baseline samples 
were collected every 20 minutes for 2 hours (2ul/min flow rate) and served as a 
measure for basal dopamine levels for each individual animal. These samples were
compared to samples taken from the same animal after systemic injection of saline or 
nicotine. All samples were collected into mcirocentrifuge tubes containing 50μl (70%) 
perchloric acid (used as a preservative and to acidify samples) and stored at -80°C until 
analysis by high performance liquid chromatography (HPLC). 
Microdialysis Probe Placement. Postmortem brain tissues were analyzed for 
probe placement and subjects with misplaced cannulae were excluded from analyses. 
Probe placement was determined by blocking the tissue at the cannula insertion site 
and placement of the probe was verified, as has been shown previously [100]. 
High Performance Liquid Chromatography. Dialysate analysis of DA content was 
determined by HPLC. The HPLC method was used to separate, identify, and quantify 
compounds in dialysate liquid collected from microdialysis experiments. Dialysate 
components were compared to known concentrations of catecholamine standards 
containing DA, norepinephine, and epinephrine (ESA catecholamine standard). A 
standard curve of concentrations for each component of the standard was determined 
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and optimized for the current study. Concentrations of samples were determined by
comparisons of retention time between standard values and unknown samples. DA 
concentrations were recorded by measuring the area under the curve (AUC), as 
calculated by ESA software, for each sample tested. The HPLC (ESA-Coulochem) 
system consisted of a refrigerated microinjector and autosampler coupled to an 
electrochemical detection system. MD-TM mobile phase (0.15 M sodium phosphate, 
2.24 mM sodium octanesulfonic acid, 0.94 mM EDTA and 10% acetonitrile, adjusted to 
pH 3.0 and filtered) was used at a flow rate of 0.6 ml/min at a gain of 10nA. The 
stationary phase consisted of a c-18 column (ESA model # 5101). To each sample, 
dihydrozybenzylamine (ESA) was added and served as an internal standard. DA was 
separated using an analytical cell and column for detecting monoamines and DA levels 
were quantified using an external standard curve. Retention time for DA was 
determined and area under the curve for each sample was calculated. From these data, 
the concentration of DA was compared to baseline levels of DA for each animal.
BDNF, GDNF, and pCREB ELISA Procedure. Twenty-four hours after testing, 
brains were removed, frozen in cold isopentane (-20oC), and stored at -80C. Acb and 
dorsal striatum DS were dissected from the tissue samples and stored at -80°C until 
use. Individual samples were weighed and 250μl cold RIPA cell lysis buffer containing 
additional protease inhibitors (Sigma, p8340, p5726, p0044, PMSF) was added to each 
sample. All samples were homogenized via mortar and pestle method, sonicated using 
a tissue dismembranator, and centrifuged at 14,000xG for 20 minutes. Supernatants 
were removed and diluted 1:2 in sample buffer (according to the product specifications 
for each ELISA test) before use. Tissue sample homogenates were analyzed using a 
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BDNF or GDNF sandwich ELISA kit (Promega, Madison, WI) or a pCREB sandwich 
ELISA kit (R&D Systems, Minneapolis, MN).  All steps and procedures for each ELISA 
were performed according to the manufacturer’s instructions. For the assays, in brief, a 
96 well plate (Nunc maxisorp, polysterene) was coated with monoclonal antibody raised 
against the target protein. Nonspecific binding was blocked before addition of known 
and unknown amounts of each protein.  The standard curve was prepared using serial 
dilutions of known amounts of BDNF, GDNF, and pCREB protein standards supplied by 
the manufacturer. The standards and samples were incubated at room temperature, 
followed by the addition of a polyclonal antibody raised against the target protein for 
each assay, which was then followed by the addition of anti-IgY horseradish peroxidase 
(HRP) conjugate. Visualization was achieved by adding 3,3´,5,5´-tetramethylbenzidine
(TMB) one solution and the reaction was stopped with 1N hydrochloric acid. All plates 
were read within 30 minutes of adding the stop solution using a Biorad plate reader with 
the absorbance set at 450nm. 
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CHAPTER 3
RESULTS
Horizontal Activity for Adolescent Males and Females
Horisontal activity for adolescent males and females is shown in Figure 1. A 4-
way repeated measures ANOVA including the factors sex, neonatal drug treatment 
(saline, quinpirole), adolescent drug treatment (saline, 0.3, 0.5, 0.7 mg/kg nicotine), and 
day of treatment (days 1 and 9) revealed a significant main effect of neonatal drug 
treatment F(1,92)=46.53, p<.01 and adolescent drug treatment F(3,92)=55.14,p<.01. 
Analyses also revealed significant 2-way interactions of sex x adolescent drug treatment 
F(3,92)=2.86,p<.04, neonatal drug treatment x adolescent drug treatment 
F(3,92)=9.82,p<.01, adolescent drug treatment x day of treatment F(3,92)=15.53,p<.01, 
and a 3-way interaction of neonatal drug treatment x adolescent drug treatment x day of 
drug treatment F(3,92)=3.26,p<.02. Newman-Keuls post hoc analyses revealed both 
male and female Group QN7 demonstrated significantly higher locomotor activation at 
day 1 of treatment as compared to all other groups (indicated by **). On day 9 of 
treatment, only male Group QN7 demonstrated significantly higher activity counts than 
all other groups (indicated by ***), whereas female Groups QN5 and QN7 were 
equivalent but demonstrated significantly higher activity counts than all other groups 
(indicated by **). Further, at day 1, male Group SN7 demonstrated significantly higher 
activity counts compared to male Group SS, whereas female Groups SN5 and SN7 
demonstrated higher activity counts compared to female Group SS at day 1 (indicated 
by *). Groups SN5 and SN7 both demonstrated higher levels of activity counts 
compared to Group SS at day 9, whereas female Groups SN3, SN5, and SN7 all 
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demonstrated significantly higher levels of activity counts than female Group SS at day 
9, demonstrating a higher level of sensitivity to nicotine in adolescent females (indicated 
by *). The asterisk (*) and double asterisk (**) both indicate p<.05.  
          Day 1        Day 9             
Figure 1a. Adolescent male locomotor sensitization to nicotine
          Day 1        Day 9             
Figure 1b. Adolescent female locomotor sensitization to nicotine
Figure 1. Horizontal activity for adolescent males (top panel) and females (bottom 
panel)
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Microdialysis Results
Adolescent males are presented with percentage of baseline as a function of 
group and time point in Figure 2. Baseline samples consisted of the first 3 samples 
taken from each animal in a drug free state. Samples after drug administration were 
compared to baseline samples from the same animal (within subject comparison). A 3-
way ANOVA with neonatal drug treatment, adolescent drug treatment and time point 
(samples 1-9) revealed significant main effects of neonatal drug treatment F(1,20)=13.0, 
p<.01, adolescent drug treatment F(1,20)=34.15,p<.01, and significant interactions of 
neonatal drug treatment x adolescent drug treatment F(1,20)=10.25, p.01, neonatal 
drug treatment x time point F(8,160) = 3.06,p<.01, adolescent drug treatment x time 
point F(8,160) = 6.10,p<01, and 3-way interaction of neonatal drug treatment x 
adolescent drug treatment x time point F(8,160) = 3.79,p<01. Post hoc analyses 
revealed that Group QN demonstrated significantly higher dopamine levels as a 
percentage of baseline compared to all other groups at 80, 100, and 120 mins post 
nicotine treatment (indicated by **). Groups QN and SN were above controls at 60-160 
min post nicotine treatment (indicated by *).  The asterisk (*) and double asterisk (**)
both indicate p<.05. Cumulative injections of nicotine (0.3mg/kg, 0.2mg/kg, 0.2mg/kg) or 
saline were given at time points 0, 20, 40, and are denoted by arrows below the graph. 
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Figure 2. Microdialysis and HPLC results, DA levels for males only         
Adolescent BDNF Results
BDNF is presented as a function of drug condition in Figure 3. In the Acb, no 
statistical effect including sex as a factor was significant, so this factor was dropped 
from the analysis. A 2 (neonatal drug treatment) x 2 (adolescent drug treatment)
ANOVA for BDNF in the Acb (Fig. 3, right panel) revealed significant main effect of 
neonatal drug treatment F(1,29) = 17.66, p<.001, adolescent drug treatment F(1,29) = 
12.07, p<.002, and a significant interaction of neonatal drug treatment x adolescent 
drug treatment F(1,29) = 4.36, p<.047. Group QN demonstrated a robust near three-fold 
increase in BDNF protein compared to controls (Group SS) as well as a significant 
better than 2-fold increase compared to Group S-N. In the dorsal striatum, no statistical 
effect including sex as a factor was significant, so this factor was dropped from the 
analysis. A 2 (neonatal drug treatment) x 2 (adolescent drug treatment) ANOVA for 
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BDNF in the dorsal striatum (Fig. 3, left panel) revealed a significant main effect of 
adolescent drug treatment F(1,28) = 10.03, p<.004. Nicotine produced a robust increase 
in BDNF in the dorsal striatum, but it was not enhanced by neonatal quinpirole. Newman 
Keuls post hoc comparisons revealed significant increases between Groups QN5 and 
SN5 compared to Group SS (control). 
Figure 3. Adolescent BDNF protein content
Adolescent GDNF Results
GDNF results are presented in Figure 4 with GDNF presented as a function of 
drug condition. As with the BDNF results, there were no significant differences with sex 
as a factor so it was dropped from the analysis. In the Acb, a 2-way ANOVA revealed a 
significant neonatal drug treatment x adolescent drug treatment interaction F(1,19) = 
7.39, p<.015 but no significant main effects of either factor. Newman Keuls post hoc 
tests revealed that Group S-N demonstrated a significant increase relative to all other 
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groups. Group S-N was increased relative to controls by 62%. In the striatum, a 2-way 
ANOVA revealed no significant main effects or interactions.
Figure 4. Adolescent GDNF protein content in DS and Acb
Adolescent pCREB Results
Phosphorylated CREB protein levels are presented as a function of drug 
condition. For the dorsal striatum, a 2-way ANOVA revealed a significant main effect of 
adolescent drug treatment F(1,17) = 7.32, p<.019. Nicotine produced a significant 
increase in p-CREB relative to controls. For the nucleus accumbens, a 2-way ANOVA 
revealed a significant main effect of neonatal drug treatment F(1,17)=8.48, p<.012 and 
a significant interaction of neonatal drug treatment x adolescent drug treatment 
F(1,17)=5.11, p<.041.
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Figure 5. Adolescent pCREB protein content in DS and Acb
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CHAPTER 4
DISCUSSION
Overall, these data demonstrate several significant behavioral and 
neurochemical changes as a result of neonatal quinpirole treatment on adolescent 
responses to nicotine. Behaviorally, as expected, adolescent animals neonatally treated 
with quinpirole demonstrated the highest increase in locomotor activity to nicotine 
administration. Additionally, in vivo microdialysis results revealed that adolescent 
animals neonatally treated with quinpirole showed a sensitized response in DA release 
in the Acb core as compared to control animals. Again, as expected, BDNF protein 
levels in the accumbens were increased by adolescent nicotine treatment and 
enhanced by neonatal quinpirole treatment. GDNF protein levels in the Acb were also 
increased by adolescent nicotine treatment; however, this effect was attenuated by 
neonatal quinpirole treatment. Finally, and possibly most importantly, pCREB protein 
were most significantly increased in the Acb by neonatal quinpirole treatment, an effect 
that was partially attenuated by adolescent nicotine administration in animals neonatally 
treated with quinpirole. This effect appears to be consistent with a robust increase in 
pCREB, which points to a possible state of anhedonia in these animals that may be 
reduced by nicotine [194]. Thus, this result would be consistent with the self-medication 
hypothesis of Glassman and colleagues [120] that nicotine may be working as a 
physiological antagonist to negative symptoms present in schizophrenia. 
Sex Differences in Adolescent Locomotor Sensitzation to Nicotine
Nicotine induced a significant increase in locomotor activity regardless of sex, a 
response that was enhanced by neonatal quinpirole treatment in both male and female 
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animals. Although animals that were treated with 0.7mg/kg nicotine showed the most 
robust increase in activity as compared to all other groups, this dose failed to result in a 
sensitized response to the activating effects of nicotine, in that animals did not
demonstrate a significant increase in activity due to subsequent administration of 
nicotine. Females neonatally treated with quinpirole demonstrated equivalent levels of 
activity counts on day 9 with both the 0.5 and 0.7 mg/kg dose of nicotine, demonstrating 
a heightened sensitivity to lower nicotine doses as compared to males neonatally 
treated with quinpirole. The adolescent locomotor sensitization results reported here are 
similar to results previously reported in adults, in that neonatal quinpirole enhanced 
sensitization to nicotine. However, sex differences were more prominent in adults, in 
that a dose of 0.5 mg/kg free base was sufficient to produce stereotypy in female adult 
rats neonatally treated with quinpirole, and this effect was not observed in adolescent 
females [126]. In regard to sex differences in adolescent animals, females showed 
increased activity as compared to males at day 9 in response to repeated nicotine 
treatment, although this difference was relatively slight. In sum, the data support the first 
hypothesis stating that adolescent nicotine treatment would a) dose dependent result in 
sex differences in adolescent locomotor sensitization; b) the locomotor activating effects 
of nicotine would be enhanced by neonatal quinpirole treatment; c) the highest nicotine 
dose (0.7mg/kg) would result in the most robust increases in locomotor activity. The 
data, however, do not show that the adolescent animals were sensitized to the 
0.7mg/kg dose of nicotine.
Data support past work from our laboratory showing increased locomotor activity 
in response to nicotine treatment in adult animals that were neonatally treated with 
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quinpirole [126]. Comparatively, adolescent animals were more sensitive to the 
activating effects of nicotine, especially females. Previous work from our laboratory 
demonstrated a lack of response to DA antagonists in males; however, in female 
animals, DA antagonism was able to block nicotine sensitization, suggesting that 
females are more sensitive to nicotine in adolescence [191].
Nicotine’s Influence on Accumbal DA Levels
In summary, neonatal quinpirole enhanced dopamine overflow produced by 
nicotine in the nucleus accumbens core by 400% over controls given nicotine at the 80 
min time point. The increase in dopamine overflow was evident at an earlier time point
in animals neonatally treated with quinpirole, with significantly increased levels over 
controls 20 minutes before controls given nicotine and persisting for 40 minutes after 
dopamine levels in controls given nicotine had returned to baseline. Rats neonatally 
treated with saline and sensitized to nicotine demonstrated a 200% increase in 
dopamine compared to baseline at peak response. These data support the hypothesis 
that neonatal quinpirole treatment would result in the highest increase in DA release 
from the Acb in adolescent animals administered nicotine.
This finding is in support of the literature that suggests an enhanced DA 
response in the Acb to systemic nicotine administration [100]. Nicotine administration in 
animals neonatally treated with quinpirole resulted in a 400% increase in DA release in 
the Acb core, which may suggest that nicotine’s rewarding properties are enhanced in 
these animals. As stated previously, repeated nicotine exposure leads to increased DA 
function in both the Acb core and shell, but increased DA overflow in the core of the Acb 
is more appropriately related to the expression of nicotine’s effect on DA [187]. The 
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current findings support this work and, additionally, increases in locomotor activity, as 
shown by locomotor sensitization in Figure 1 show that nicotine induced increases in 
DA overflow correlate with an increase in locomotor activity. 
Nicotine’s Influence on Adolescent BDNF
From these analyses, it is clear that nicotine produced a significant increase in 
BDNF in both brain areas. In the Acb, nicotine administration lead to a 2-fold increase in 
BDNF levels in animals neonatally treated with quinpirole, as compared to all other 
groups. These results show that adolescent nicotine administration increased BDNF, 
and this appears to be most likely to be affected by neonatal quinpirole treatment. 
Additionally, these results are consistent with findings in human schizophrenic smokers.
These results support the hypothesis that adolescent nicotine treatment would result in 
increased BDNF protein levels in the Acb and DS and that neonatal quinpirole treatment 
would enhance this effect.
Increased BDNF levels in the Acb and striatum are consistent with findings in the 
literature that suggest a role for BDNF in synaptic plasticity [33, 145]. Increased BDNF 
levels correlate with increased locomotor activity and increased motivation for drug 
taking behaviors. The current study showed a robust, 3-fold increase in BDNF levels in 
the Acb, and according to the literature, this increase suggests neuronal adaptations in 
the brain in response to nicotine exposure [140], which would lead to eventual nicotine 
addiction, and given that DA receptor supersensitivity leads to enhanced BDNF levels 
over control animals given nicotine, it is likely that the addictive properties of nicotine 
would be more pronounced in schizophrenic versus normal smokers.  
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Nicotine’s influence on GDNF
Interestingly, GDNF protein levels were unchanged in all treatment groups in the 
dorsal striatum. In the Acb, adolescent nicotine administration resulted in a significant 
increase in GDNF protein levels above all other groups, but there was no significant 
effect of neonatal quinpirole treatment. Typically, GDNF levels are decreased in 
response to exposure to other drugs of abuse; however, nicotine’s effects on GDNF 
have not been examined, especially in the context of the immature DA system of 
adolescents. These data do not support the hypothesis that adolescent nicotine 
treatment would decrease GDNF levels in the Acb and striatum, and that neonatal 
quinpirole treatment would lead to further decreases in GDNF protein levels.
In regard to nicotine’s influence on GDNF protein levels in the striatum and Acb, 
these findings suggest that the nicotine administration in adolescence leads to the 
increased GDNF levels in the Acb. Findings in the literature, in which other DA agonists, 
such as cocaine were used [169], suggest that GDNF levels should be decreased in 
response to nicotine administration, contrary to the current experiments, demonstrating 
an increase in GDNF in the Acb. However, nicotine’s effects on GDNF levels in the 
midbrain have not been studied. Additionally, immaturity and dynamic growth of the 
adolescent DA circuitry [137] may contribute to unexpected results. Neonatal quinpirole 
treatment did not enhance accumbal GDNF levels in response to nicotine, as seen in 
control animals given nicotine, which may suggest that increased sensitivity of the D2
receptor leads to abnormal GDNF function in the brain. However, further exploration of 
this result is needed in order to better explain this relationship, such as examination of 
the effects of nicotine on GDNF levels in the adult brain.
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Nicotine’s influence on pCREB
Accumbal pCREB levels were significantly increased in animals neonatally 
treated with quinpirole, which may underlie anxiety and increased drug seeking 
behaviors.  Nicotine administration in adolescent animals partially attenuated the 
increase in pCREB levels in the Acb, which would suggest that nicotine is decreasing 
stress levels in this group. These results support the hypothesis that neonatal quinpirole 
treatment will result in an increase in pCREB levels in the Acb and that adolescent 
nicotine administration would reduce this effect.
Data are consistent with work by Pascual et al. [130] that showed a lower dose 
[0.21 mg/kg free base] of nicotine as compared to the current study [0.5mg/kg free 
base] resulted in an increase of p-CREB in the Acb and DS. Interestingly, pCREB levels 
in animals neonatally treated with quinpirole were partially attenuated by nicotine 
treatment, as compared to animals neonatally treated with quinpirole that received 
saline in adolescence. This result suggests that pCREB protein levels may be a 
neurochemical marker for nicotine’s use as a self-medication of negative symptoms in 
this model. As previously shown in rodents, stress induced by fear conditioning causes 
increased pCREB in the Acb [194]. In our model, we have shown that neonatal 
quinpirole treatment leads to a 4-fold increase in pCREB in the Acb of adolescent 
animals, and this increase is attenuated by adolescent nicotine treatment. These data 
suggest that nicotine administration in animals neonatally treated with quinpirole is 
rewarding because of its ability to decrease stress. Nicotine administration in adult and 
adolescent rats also leads to increased preference ratios in CPP and also increased 
pCREB in the VTA and Acb, suggesting that this increased preference is at least 
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partially modulated by changes in intracellular processes controlled by CREB activation. 
The increase of p-CREB is consistent with the notion put forth by Nestler and Carlezon 
[176] that robust and sustained increases in accumbal CREB may be an indicator for 
anhedonia in these animals, consistent with negative symptoms in schizophrenia. 
BDNF, GDNF, and pCREB: Is There a Relationship?
Changes in the protein levels of BDNF, GDNF, and pCREB in relation to 
neonatal quinpirole treatment and in relation to adolescent nicotine administration have 
been demonstrated by this study; however, the real question may lie in how these 
factors are related to each other in the brain. Are these markers for plasticity related or 
is this finding just an interesting result within the manipulation of our model? This is 
certainly a question to be addressed in the future; however, it seems that the underlying 
connection between altered protein levels of BDNF, GDNF, and pCREB in the neonatal 
quinpirole model is largely due to modulation of the DA system. As these experiments 
have demonstrated, increased sensitivity of the DA receptor significantly affects the 
expression of BDNF, GDNF, and pCREB, all of which are suggested to play a role in 
brain plasticity. DA increases result in an increase in cell activity, leading to increased
BDNF in response to nicotine, which has also been shown in human schizophrenia.
Increases in stress are known to affect pCREB in animals and humans, and stress 
reduction is one common reason for smoking, stated by schizophrenic humans [122]. In 
our model, nicotine administration partially attenuated this increase in pCREB in the 
Acb, suggesting that nicotine may also be alleviating stress in this model, which would 
contribute to the motivation to increase nicotine intake, as shown by CPP studies from 
our lab, in which animals were more likely to spend time in a context that had been 
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previously paired with nicotine than a context that had been paired with saline on a drug 
free trial [195]. GDNF has been shown to be an inversely related to DA levels, 
suggesting that increases in DA would result in decreases in GDNF. Results from this 
study showed that nicotine administration increased GDNF in control animals; however, 
neonatal quinpirole treatment reduced that effect.  However, it is not certain that BDNF, 
GDNF, and pCREB are influencing each other, because although CREB regulates 
BDNF, it is far downstream and regulates other proteins as well. GDNF has also been 
shown to be regulated by pCREB; however, there is very little supporting evidence for 
this relationship. There is also little evidence regarding the effects of nicotine on GDNF 
in the brain and no work has focused on adolescence. 
Alpha7 nAChRs and schizophrenia
Postmortem, it has been reported that, schizophrenics have decreased α7 
nAChR binding in the brain; however, the majority of this work has focused on the 
hippocampus [42]. There have not been any reports showing any change in a4b2 
nAChRs in schizophrenics. Behavioral studies have primarily focused on hippocampal 
α7 nAChRs as therapeutic targets for improving sensorimotor gating deficits that are 
known to exist in schizophrenics and have been suggested to be the root of cognitive 
deficits in the disorder [96]. In rodents, infusion of an α7 nAChR agonist into the Acb 
leads to increased nicotine self-administration in normal animals, which suggests that a 
decrease in function of α7 nAChRs contributes to increased motivation for nicotine 
[186]. In postmortem human studies, adult nonsmoking schizophrenics have decreased 
α7 nAChR mRNA and protein levels in the hippocampus than healthy nonsmokers, and 
smoking increases α7 nAChR mRNA and protein to control levels, suggesting abnormal 
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trafficking of these receptors [96]. However, this evidence in humans only pertains to a 
difference in α7 nAChR function in the hippocampus. Currently there is no evidence 
suggesting a change in α7 in brain areas mediating drug reward or on nAChRs in 
reward areas of the brain in schizophrenic smokers, and there are no data 
characterizing α7 nAChRs at earlier developmental stages in schizophrenics. 
Interestingly, Tizabi and colleagues reported [70] that neonatal quinpirole 
resulted in a significant upregulation of alpha7 nAChRs in the striatum at P30 but no 
change in alpha4beta2 nAChRs in this same brain area. Obviously, P30 is near when 
nicotine treatment began in the present study. Alpha7 receptors have been primarily 
identified as calcium (Ca+2) channels. Calcium allows neurotransmitter release through 
entry into presynaptic terminals, causing depolarization of the cell, which allows for 
neurotransmitter release at the synapse. In the VTA and striatum, α7 receptors are 
localized on glutamatergic terminals, and the mechanism through which α7 nAChRs 
increase dopamine release in these areas has been attributed to glutamate function at 
the DA terminal [36], [39]. Research has shown that nicotine binding at the α7 receptor 
increases glutamate release, excites dopamine terminals, and leads to increased 
dopamine release. Glutamate induced DA release has been shown in vitro, as 
glutamate stimulates release of [3H] dopamine from rat striatal slices [187], an effect 
that appears to be mediated by both types of glutamate receptor (AMPA/kainate and N-
methyl-D-aspartate) present on dopaminergic nerve terminals [188]. Additionally, in vivo 
striatal infusion of NMDA [196-198] or AMPA [199] increases local release of dopamine. 
This is in contrast to the activation of α4β2 nAChRs that has been shown to directly 
stimulate the release of dopamine from dopaminergic terminals in the neostriatum [48]. 
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Therefore, it appears that α7 nAChRs indirectly influence dopaminergic activity in the 
striatum through a glutamatergic mechanism, whereas α4β2 nAChRs directly influence 
dopamine release in the striatum through location of these receptors on dopaminergic 
terminals.
Therefore, in our model, one mechanism by which nicotine may be working is 
through the upregulation of alpha7 nAChRs. Although this has been shown only in the 
dorsal striatum, we assume the same phenomena is occurring in the Acb based on the 
fact that the source of dopamine for both areas is from the dopamine midbrain neurons. 
I hypothesize that nicotine, as an agonist to upregulated alpha7 nAChRs in rats 
neonatally treated with quinpirole, would produce an increase in dopamine overflow in 
these animals as compared to controls. This hypothesis would need to be verified with 
the use of a selective α7 antagonist administered before nicotine in rats neonatally 
treated with quinpirole. Our lab is currently working towards a series of experiments to 
analyze the role of nAChRs in this effect. 
Ultimately, this project was designed to provide insight towards pharmaceutical 
targets for smoking cessation in schizophrenics. Given the data that have been 
presented, along with findings in the literature, it is apparent that intervention for 
smoking behaviors in adolescents is a clear target for reducing smoking, and potentially 
reducing the exacerbation of symptoms related to psychoses, such as schizophrenia. It 
is possible that modulation pCREB, GDNF, and BDNF would be potential targets for 
pharmaceutical therapies; however, this would require more in-depth experiments 
involving these markers for neuronal plasticity. 
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